Search

Orange Grove Bio Appoints Key Leadership & New Academic Collaboration

The following excerpt was taken from Globe Newswire -- continue reading here.


Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D., a renowned cancer clinician and researcher, as chair of the company’s scientific advisory board. Additionally, the company appointed Rob Scott, M.D., retired chief medical officer and head of development at AbbVie, to its advisory board and named Michael Kalos, Ph.D., as the head of its cellular therapy business unit. These appointments further strengthen Orange Grove’s growing leadership team and support the company’s mission of developing new therapeutics for patients by harnessing the significant research potential found in universities and academic medical centers across the United States.